OVID (Ovid Therapeutics) Cyclically Adjusted PS Ratio: (As of Jul. 02, 2026)


OVID Ovid Therapeutics Inc OVID
48 GF Score
Price $2.69
GF Value $8.41
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ovid Therapeutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ovid Therapeutics  (NAS:OVID) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Ovid Therapeutics Cyclically Adjusted PS Ratio Related Terms


Ovid Therapeutics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Ovid Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ovid Therapeutics Cyclically Adjusted PS Ratio Chart

Ovid Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.64

Ovid Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 1.23 1.64 0.00

OVID vs ARTV, CCCC, RZLT: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Ovid Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovid Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's Cyclically Adjusted PS Ratio falls into.


OVID
48GF Score
Ovid Therapeutics Inc OVID
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ovid Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Ovid Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Ovid Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Ovid Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.000 251.989 0.000
201809 0.000 252.439 0.000
201812 0.000 251.233 0.000
201903 0.000 254.202 0.000
201906 0.000 256.143 0.000
201909 0.000 256.759 0.000
201912 0.000 256.974 0.000
202003 0.000 258.115 0.000
202006 0.000 257.797 0.000
202009 0.116 260.280 0.147
202012 0.089 260.474 0.113
202103 3.130 264.877 3.902
202106 0.000 271.696 0.000
202109 0.000 274.310 0.000
202112 0.000 278.802 0.000
202203 0.021 287.504 0.024
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.001 296.797 0.001
202303 0.001 301.836 0.001
202306 0.001 305.109 0.001
202309 0.002 307.789 0.002
202312 0.002 306.746 0.002
202403 0.002 312.332 0.002
202406 0.002 314.175 0.002
202409 0.002 315.301 0.002
202412 0.001 315.605 0.001
202503 0.002 319.799 0.002
202506 0.088 322.561 0.090
202509 0.002 324.800 0.002
202512 0.009 324.054 0.009
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Ovid Therapeutics (OVID) Overvalued in 2026?

Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued. The current stock price of $2.69 is trading 68% below its estimated GF Value™ of $8.41. GuruFocus considers Ovid Therapeutics to be Possible Value Trap.

Key valuation signals for OVID:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $8.41 vs. price of $2.69 (68% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ovid Therapeutics Business Description

Other Exchanges 1OT:Germany
Address 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
48GF Score

Get the complete analysis for OVID

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.69
Price
$8.41
GF Value